On May 14, 2024, the Diabetes, Obesity and Metabolism published “Risks of Peri- and Post-Operative Complications With Glucagon-like Peptide-1 Receptor Agonists” by Klonoff, David; Diabetes Research Institute, Kim, Sun; Stanford University School of Medicine, Galindo, Rodolfo J. J.; University of Miami Miller School of Medicine, Joseph, Jeffrey; Thomas Jefferson University, Department of Anesthesiology, The Jefferson Artificial Pancreas Center, Garrett, Valerie; Atropos Health, Gombar, Saurabh ; Atropos Health, Aaron, Rachel; Diabetes Technology Society, Tian, Tiffany; Diabetes Technology Society, and Kerr, David; Center for Health Systems Research, Sutter Health.
Read the full paper in Diabetes, Obesity and Metabolism: A journal of pharmacology and therapeutics
Overview:
-
American Society of Anesthesiologists (ASA) expressed safety concerns and outlined that patients on GLP-1s should pause dosing a week before any surgical operations.
-
Though this guideline was not based on any substantial evidence, it was adopted by health systems across the country.
-
Many patients experienced complications as a result of halting diabetes treatment plans and same-day surgical cancellations spiked, resulting in revenue loss for health systems.
Conclusions:
For the study, data from over 130M anonymous patients was reviewed, and eventually narrowed down to 13K patient data sets that best fit the criteria.
-
Atropos Health provided access to real-world data (RWD), Real World Fitness Scores™ (RWFS) for the datasets based on the question, and a final report (Prognostogram).
It was determined that using GLP-1s the week of surgery did not increase the risk for any of the six possible side effects the ASA predicted.
To learn how Atropos Health can accelerate and supplement your research with Real-World Evidence (RWE), contact info@atroposhealth.com